Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) and DexCom (NASDAQ:DXCM – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and recommmendations for Intelligent Bio Solutions and DexCom, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 1 | 1 | 0 | 0 | 1.50 |
| DexCom | 0 | 2 | 24 | 2 | 3.00 |
DexCom has a consensus price target of $95.50, indicating a potential upside of 19.75%. Given DexCom’s stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Intelligent Bio Solutions.
Volatility and Risk
Intelligent Bio Solutions has a beta of 4.48, indicating that its share price is 348% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Insider & Institutional Ownership
33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 2.8% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Intelligent Bio Solutions and DexCom’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -269.28% | -150.00% | -83.38% |
| DexCom | 19.42% | 37.77% | 15.98% |
Earnings and Valuation
This table compares Intelligent Bio Solutions and DexCom”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $4.22 million | 1.21 | -$12.43 million | ($6.38) | -0.24 |
| DexCom | $4.66 billion | 6.38 | $836.30 million | $2.55 | 31.28 |
DexCom has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Summary
DexCom beats Intelligent Bio Solutions on 13 of the 15 factors compared between the two stocks.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a medical technology company focused on non-invasive testing and diagnostic solutions. Its flagship offering is the Intelligent Fingerprinting Drug Screening System, which analyzes trace sweat collected from a person’s fingertips to screen for drugs. The system combines a portable reader with single-use fingerprint test cartridges. Its compact format is designed for use in settings such as workplaces, law enforcement, drug treatment and rehabilitation programs, and other organizations that conduct screening.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
